Research
Siponimod
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive Multiple Sclerosis patients
Cognitive Rehabilitation Research
NUI Galway are looking for people to take part in a new programme
New Research Programme
Queens researchers in £2 million bid to reverse the damage of Multiple Sclerosis